PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|April 4, 2014
EDQM Launches Counterfeit Drug Database
Author(s)Pharmaceutical Technology Editors
EDQM has launched a database, Know-X, which collates reports on counterfeit/falsified medical products that have been detected in Council of Europe member states.
Advertisement
The European Directorate for the Quality of Medicines & HealthCare (EDQM) announced the launch of a new database, Know-X, which collates reports on counterfeit/falsified medical products that have been detected in Council of Europe member states.
The user-friendly tool was developed to assist officials by expanding knowledge and awareness of the problem of counterfeit/falsified medicines, provide a basis for the exchange of information, highlight and encourage collaboration between health and law enforcement authorities, and foster the sharing of analytical information on the testing of counterfeit/falsified and other illegal medicines within the Network of Official Medicines Control Laboratories (OMCLs), EDQM reports in a statement.
The database contains details on closed cases of counterfeit/falsified medical products, technical information on the testing performed, the authorities involved and what actions were taken. The information provided is gathered from OMCLs, health authorities, regulatory agencies, medical products surveillance authorities, customs, and police and is intended to provide governments with decision aids for the management and prevention of specific risks.
Access can be requested by officials working for a competent health or law enforcement authority in a Council of Europe member state or in a state party to the
Source:
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
In commercial tablet or capsule operations, validation helps protect the site’s ability to produce, release, and supply product without repeated disruption. This article discusses validation as a technical control system that supports manufacturing continuity.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
Advertisement
Advertisement